DMAC

DiaMedica Therapeutics' stock has fluctuated between $3.47 and $10.42 over the past 52 weeks, with a share price of $6.52 as of May 7, 2026. The company reported full-year 2025 and first-quarter 2026 financial results, with the latter showing a net loss of $10.0 million due to increased R&D expenses. Enrollment delays in the ReMEDy2 trial have pushed the interim analysis to Q4 2026. Analyst ratings are mixed, with some downgrades and others maintaining a "Moderate Buy" rating with a target price of $12.33. As of March 31, 2026, the company held $51.3 million in cash and short-term investments, expected to fund operations through 2027.